2017-11-08T14:01:32-06:00 2016-12-31 521855942 Tate and Tryon 2021 L Street NW Suite 400 Washington DC 20036 990 2016-01-01 231682043 American Society For Clinical Pharmacology and Therapeutics AMER 7038366981 528 NORTH WASHINGTON STREET ALEXANDRIA VA 22314 sharon swan Chief Executive Officer 7038366981 2017-11-08 1 R Michael Sorrells P00001737 2022932200 216.59.105.130 2017-11-08 14:01:28 ES P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 5BC65B47B3A1F1CE2534BD8A8DAEFAC1BF945F16 2016 2021-01-29 14:40:06Z Sharon Swan 528 NORTH WASHINGTON STREET ALEXANDRIA VA 22314 4035187 0 X WWW.ASCPT.ORG X 1900 DC ADVANCING CLINICAL PHARMACOLOGY, TRANSLATIONAL MEDICINE AND THERAPEUTICS FOR THE BENEFIT OF PATIENTS AND SOCIETY. 11 11 11 400 2912 0 30259 99311 1844898 3348943 92934 126592 967504 25022 2935595 3599868 22500 27750 0 0 1093031 1321546 0 0 3627 2137606 2391148 3253137 3740444 -317542 -140576 5370032 5268980 172125 130112 5197907 5138868 X Advancing clinical pharmacology, translational medicine and therapeutics for the benefit of patients and society. 0 0 1742958 27750 1710104 Annual Meeting: THE ASCPT ANNUAL MEETING IS AN INTERNATIONAL MEETING THAT ATTRACTS PARTICIPANTS FROM AROUND THE WORLD. A SPECTRUM OF TOPICS RELATING TO THE CONTINUUM OF DRUG DISCOVERY, DEVELOPMENT, REGULATION, AND UTILIZATION ARE DISCUSSED. THE MEETING OFFERS EDUCATIONAL SESSIONS AND POSTER PRESENTATIONS, LECTURES FROM TOP PROFESSIONALS IN THE INDUSTRY, AS WELL AS NETWORKING OPPORTUNITIES WITH CLINICAL PHARMACOLOGISTS FROM AROUND THE WORLD. THERE IS ALSO AN EXHIBIT HALL WITH REPRESENTATIVES FROM VARIOUS COMPANIES. 1149610 0 995220 Journal: CLINICAL PHARMACOLOGY AND THERAPEUTICS (CPT) IS THE AUTHORITATIVE CROSS-DISCIPLINARY JOURNAL IN EXPERIMENTAL AND CLINICAL MEDICINE DEVOTED TO PUBLISHING ADVANCES IN THE NATURE, ACTION, EFFICACY AND EVALUATION OF THERAPEUTICS. IT CONTINUES TO SEE IMPROVEMENTS IN THE NUMBER OF MANUSCRIPTS RECEIVED AND INCREASES IN SUBSCRIPTIONS.CPT: PHARMACOMETRICS AND SYSTEMS PHARMACOLOGY (CPT:PSP) IS AN ONLINE, FULLY OPEN ACCESS JOURNAL. CPT:PSP PROVIDES A UNIQUE INTERNATIONAL FORUM FOR SCIENTISTS IN THE PHARMACOMETRICS AND SYSTEMS PHARMACOLOGY SPACE.Clinical and Translational Science (CTS), the newest journal of the American Society for Clinical Pharmacology and Therapeutics, highlights original translational medicine research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. New content is published regularly. 576172 643619 Member Services: MEMBERSHIP IN ASCPT OFFERS A NUMBER OF BENEFITS WHICH DIRECTLY IMPACT ITS MEMBERS AND THEIR PROFESSIONAL DEVELOPMENT. IT PROVIDES A VARIETY OF INFORMATION TOOLS, SUCH AS THE CPT JOURNAL, WEBSITE AND EMAIL NEWSLETTER, EDUCATIONAL OPPORTUNITIES, SUCH AS THE ANNUAL MEETING, AND PROFESSIONAL DEVELOPMENT OPPORTUNITIES. 3468740 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 46 0 1 11 1 1 1 0 0 0 0 0 0 0 0 0 X 11 11 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 VA X The Society 7038366981 528 NORTH WASHINGTON STREET ALEXANDRIA VA 22314 Kellie Reynolds PharmD President 5.00 X X 0 0 0 Dan Hartman MD FCCP President-Elect 5.00 X X 0 0 0 Julie A Johnson PharmD Immediate Past President 5.00 X X 0 0 0 Walter Kraft MD FACP Treasurer 5.00 X X 0 0 0 Anne C Heatherington PhD Director 5.00 X 0 0 0 Sean Hennessy PharmD PhD Director 5.00 X 0 0 0 David Y Mitchell PhD Director 5.00 X 0 0 0 Virginia Ginny D Schmith PhD FCP Director 5.00 X 0 0 0 Jill Fiedler-Kelly Phd Director 5.00 X 0 0 0 Aubrey Stoch MD Director 5.00 X 0 0 0 Paolo Vicini PhD MBA Director 5.00 X 0 0 0 Sharon J Swan FASAE CAE Chief Executive Officer 60.00 X 384411 0 43363 Elise Laffman-Johnson Chief Operating Officer 40.00 X 174038 0 12303 558449 0 55666 2 0 1 0 FREEMAN AUDIO VISUAL INC PO BOX 650519 DALLAS TX 752650519 AUDIO VISUAL SERVICES 275902 1 99311 99311 Annual Meeting Registr 900099 1281799 1281799 journals 900099 995220 992308 2912 Membership Dues 900099 643619 643619 Exhibits 900099 262208 262208 AM Sponsorships 900099 166097 166097 3348943 74049 74049 18060 18060 487862 435319 52543 52543 52543 Miscellaneous 900099 6962 6962 6962 3599868 3346031 2912 151614 27750 27750 618118 470516 147602 567386 477094 90292 730 730 67598 5120 62478 67714 57215 10499 24784 24784 87562 5667 81895 19770 19770 204473 184253 20220 104764 82118 22646 20222 20222 38012 38012 84399 63548 20851 1130991 1097333 33658 3641 3641 51132 51132 26892 26892 AWARDS/HONORARIUM 245961 234178 11783 MEMBERSHIP Services + R 141013 140960 53 Strategic Plan & Busine 116232 9513 103092 3627 EDITORIAL EXPENSES 50316 50316 40984 563159 -522175 3740444 3468740 268077 3627 149221 254442 1243078 888566 4252 0 1108269 396115 740659 712154 2682302 2885173 550520 528645 5370032 5268980 0 66 131534 59396 40591 70650 172125 130112 X 4933383 4854931 264524 283937 5197907 5138868 5370032 5268980 -140576 81537 0 X X 1 X 0 0 0 X 113713 98684 46169 30259 99311 388136 3006395 2615205 3165820 2790322 3346031 14923773 3120108 2713889 3211989 2820581 3445342 15311909 0 976902 932521 1226890 916103 956864 5009280 976902 932521 1226890 916103 956864 5009280 10302629 65687 91966 102071 108018 92109 459851 65687 91966 102071 108018 92109 459851 11287 7707 3134 0 0 22128 18301 1885 12186 3547 6962 42881 3215383 2815447 3329380 2932146 3544413 15836769 0.65060 0.02900 X Schedule A, Part III, Line 12, Explanation of Other Income: Income from Activities not Normally Recurring RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3720673 3720673 336034 84009 0 0 281814 287046 311662 336034 1216556 1824834 70454 71762 77916 84009 304141 456212 442881 38541 36173 40810 2848 473937 451852 3628 781 10059 3321 442881 471079 6043 26911 47961 4220 451852 411569 60083 45311 42119 3765 471079 427130 59572 29502 101627 3008 411569 0.40000 0.00000 0.60000 0 0 186000 186000 577816 192605 385211 195657 62680 132977 123676 115710 7966 25120 25120 0 712154 DUE TO INTERNATIONAL SOCIETY OF PHARMACOMETRICS 70650 70650 X Part V, Line 4: purpose of endowment: THE BOARD OF DIRECTORS HAS DESIGNATED CASH AND INVESTMENTS TO BE SET ASIDE TO MEET AT LEAST THREE MONTHS WORTH OF OPERATING EXPENSES. THE BOARD HAS ALSO DESIGNATED CERTAIN INVESTMENTS AND THE INCOME RELATED TO THOSE INVESTMENTS ACCOUNTS FOR PAYMENT OF THE SOCIETY'S AWARD PROGRAMS AT ITS ANNUAL MEETING. THE AWARDS PROGRAMS FOR WHICH INVESTMENTS HAVE BEEN SET ASIDE INCLUDE THE WILLIAM B. ABRAMS AWARD, THE RAWLS-PALMER AWARD, the Sheiner-Beal Award, the Gary Neil Prize, AND THE SCIENTIFIC AWARDS COMMITTEE. Part X, Line 2: The Society has evaluated its tax positions for all open tax years. Currently, the tax years open and subject to examination by the Internal Revenue Service are the 2014, 2015, and 2016 tax years. However, the Society is not currently under audit. Based on the evaluation of the Society's tax positions, management believes all tax positions taken would be upheld under an examination. Therefore, no provisions for the effects of uncertain tax positions have been recorded for the year ended December 31, 2016. 1 RAWLS-PALMER PROGRESS IN MEDICINE AWARD 1 2000 FDA ABRAMS AWARD LECTURE 1 500 GARY NEIL PRIZE 1 2500 LEON I. GOLDBERG YOUNG INVESTIGATOR AWARD 2 2000 Oscar B. Hunter Award 1 1500 Abrams 1 1000 2016 President Trainee Award 30 17250 Henry Elliot Dist Svc award 1 1000 Part I, Line 2: ASCPT MAINTAINS RECORDS TO SUBSTANTIATE THE AMOUNT OF GRANTS OR ASSISTANCE, THE GRANTEES' ELIGIBILITY FOR THE GRANTS, AND THE SELECTION CRITERIA USED TO AWARD THE GRANTS. EACH YEAR ASCPT'S AWARDS PROGRAM PROVIDES AN ARRAY OF AWARDS THAT RECOGNIZE OUTSTANDING SCIENCE AND ACHIEVEMENT IN CLINICAL PHARMACOLOGY. ASCPT'S AWARDS SPAN THE CONTINUUM OF CLINICAL PHARMACOLOGY, TRANSLATIONAL MEDICINE, AND THERAPEUTICS. THE ARRAY OF AWARDS IS DESIGNED TO RECOGNIZE EVERY TURNING POINT IN THE CAREER PATH FROM YOUNG INVESTIGATOR TO SEASONED SCIENTIST WITH THE FOCUS ON EXCEPTIONAL ACHIEVEMENTS IN THE DIMENSIONS THAT THE AWARDS ARE FOCUSED. CANDIDATES ARE NOMINATED BY COLLEAGUES FOR CONSIDERATION FOR AN ASCPT AWARD. ALL NOMINATIONS ARE VETTED BY AN APPOINTED AWARDS SELECTION TASK FORCE COMPRISED OF ASCPT MEMBERS. LETTERS OF RECOMMENDATION AND CURRICULUM VITAE ARE REVIEWED AND ULTIMATELY DECISIONS ARE MADE BY THE AWARDS SELECTION TASK FORCE ON EACH RECIPIENT OF AN ASCPT AWARD. GARY NEIL PRIZE FOR INNOVATION IN DRUG DEVELOPMENT ELIGIBILITY: INDIVIDUALS AS WELL AS TEAMS WHO HAVE DEMONSTRATED LEADERSHIP IN THE APPLICATION OF SIGNIFICANT, INNOVATIVE SCIENCE TO CLINICAL DRUG DEVELOPMENT. THE AWARD IS OPEN TO INDIVIDUALS FROM ALL CLINICAL PHARMACOLOGY EMPLOYMENT SECTORS. PRIZE AND PRESENTATION: THE GARY NEIL PRIZE FOR INNOVATION IN DRUG DEVELOPMENT WILL BE PRESENTED AT THE ASCPT ANNUAL MEETING. THE RECIPIENT WILL RECEIVE A PLAQUE AND A $2,500 PRIZE. TRAVEL EXPENSES, HOTEL EXPENSES AND MEETING REGISTRATION WILL BE REIMBURSED BY THE SOCIETY. LEON I. GOLDBERG EARLY INVESTIGATOR AWARD* *PREVIOUSLY LEON I. GOLDBERG YOUNG INVESTIGATOR AWARD FROM 1986-2015 ELIGIBILITY: THE NOMINEE CAN BE AN ACADEMIC, INDUSTRIAL, OR REGULATORY SCIENTIST WHO HAS MADE A SUBSTANTIAL CONTRIBUTION TO CLINICAL PHARMACOLOGY WITHIN 10 YEARS OF THE COMPLETION OF AN ADVANCED DEGREE AND/OR A POST-DOCTORAL FELLOWSHIP OR RESIDENCY PROGRAM. AN IMPORTANT ASPECT IS THAT THE RECIPIENT WILL BE ABLE TO DELIVER AN ENGAGING PRESENTATION ABOUT THE IMPACT OF HIS/HER RESEARCH. THE AWARD IS INTENDED TO FOSTER THE CANDIDATE'S POTENTIAL FOR SIGNIFICANT CONTRIBUTIONS TO THE FUTURE OF CLINICAL PHARMACOLOGY. THE NOMINATOR'S ASSESSMENT AND LETTERS OF RECOMMENDATION SHOULD CONTAIN EVIDENCE THAT THE CANDIDATE HAS DOCUMENTED SCIENTIFIC CONTRIBUTIONS, AS EVIDENCED BY EITHER WELL CITED PUBLICATIONS, GRANTS, PATENTS, INDEPENDENT INFLUENCE ON IMPORTANT DRUG DEVELOPMENT OR REGULATORY DECISIONS, OR OTHER RECOGNITIONS AS MAY BE RELEVANT. THERE ARE NO RESTRICTIONS CONCERNING THE SCIENTIFIC FIELD IN WHICH NOMINEES HAVE EARNED THEIR DOCTORAL DEGREES. ALTHOUGH IT IS ENCOURAGED, A NOMINEE NEED NOT BE A MEMBER OF THE SOCIETY. PRIZE AND PRESENTATION: THE LEON I. GOLDBERG EARLY INVESTIGATOR AWARD IS PRESENTED AT THE ASCPT ANNUAL MEETING. THE RECIPIENT WILL DELIVER A LECTURE ON HIS/HER WORK. IN ADDITION, THE RECIPIENT OF THE AWARD WILL RECEIVE A PLAQUE AND A $1,000 PRIZE. TRAVEL EXPENSES, HOTEL EXPENSES AND MEETING REGISTRATION ARE REIMBURSED BY THE SOCIETY. OSCAR B. HUNTER CAREER AWARD IN THERAPEUTICS* *PREVIOUSLY OSCAR B. HUNTER MEMORIAL AWARD FROM 1955-2015 ELIGIBILITY: THE NOMINEE CAN BE AN ACADEMIC, INDUSTRIAL, OR REGULATORY SCIENTIST WHO HAS DEMONSTRATED A SUSTAINED RECORD OF LIFELONG CONTRIBUTIONS TO CLINICAL PHARMACOLOGY AND DISSEMINATION OF KNOWLEDGE WHO WILL BE ABLE TO GIVE AN ENGAGING PRESENTATION ABOUT HIS/HER CAREER AND THE IMPACT OF HIS/HER WORK. THE NOMINATOR'S ASSESSMENT AND LETTERS OF RECOMMENDATION SHOULD PROVIDE EVIDENCE OF THE NOMINEE'S EXEMPLARY CAREER AS A LEADER, INCLUDING SUFFICIENT DOCUMENTED SCIENTIFIC CONTRIBUTIONS, AS EVIDENCED BY EITHER HIGH IMPACT PUBLICATIONS, PATENTS, INDEPENDENT INFLUENCE ON IMPORTANT DRUG DISCOVERY, DRUG DEVELOPMENT OR REGULATORY DECISIONS, OR OTHER RECOGNITIONS AS MAY BE RELEVANT. PARTICULAR EMPHASIS SHOULD BE PROVIDED ON THE LIFETIME CONTRIBUTIONS OF THIS NOMINEE AND THE IMPACT OF HIS/HER ACCOMPLISHMENT TO CLINICAL PHARMACOLOGY. THE NOMINEE MUST BE A WELL-RECOGNIZED LEADER IN CLINICAL PHARMACOLOGY, BUT DOES NOT NEED TO BE AN ASCPT MEMBER. PRIZE AND PRESENTATION: THE OSCAR B. HUNTER CAREER AWARD IN THERAPEUTICS IS PRESENTED AT THE ASCPT ANNUAL MEETING. THE RECIPIENT WILL PRESENT A LECTURE SUMMARIZING THE WORKS THAT FORM THE BASIS OF THE AWARD. IN ADDITION, THE RECIPIENT OF THE AWARD WILL RECEIVE A BRONZE MEDAL MOUNTED ON A PLAQUE AND A $1,500 PRIZE. TRAVEL EXPENSES, HOTEL EXPENSES AND MEETING REGISTRATION WILL BE REIMBURSED BY THE SOCIETY. RAWLS-PALMER PROGRESS IN MEDICINE AWARD ELIGIBILITY: A NOMINEE CAN BE AN ACADEMIC, INDUSTRIAL, OR REGULATORY SCIENTIST WHO IS WIDELY RECOGNIZED FOR HIS/HER TRANSFORMATIONAL AND/OR TRANSLATIONAL DISCOVERIES OR INNOVATIVE APPROACHES IMPACTING CLINICAL PHARMACOLOGY RESEARCH AND CLINICAL PRACTICE. THE NOMINATOR'S ASSESSMENT AND LETTER(S) OF RECOMMENDATION SHOULD PROVIDE EVIDENCE OF THE NOMINEE'S EXEMPLARY RECORD, INCLUDING SUFFICIENT DOCUMENTED SCIENTIFIC CONTRIBUTIONS FROM RESEARCH THAT LEAD TO DIRECT APPLICATIONS IN PATIENT CARE, AS EVIDENCED BY EITHER WELL CITED PUBLICATIONS, PATENTS, INDEPENDENT INFLUENCE ON IMPORTANT DRUG DEVELOPMENT OR REGULATORY DECISIONS, OR OTHER RECOGNITIONS (AS MAY BE RELEVANT). A NOMINEE DOES NOT NEED TO BE AN ASCPT MEMBER. PRIZE AND PRESENTATION: THE RAWLS-PALMER PROGRESS IN MEDICINE AWARD IS PRESENTED AT THE ASCPT ANNUAL MEETING. THE RECIPIENT WILL PRESENT A LECTURE FOCUSING ON RECENT DEVELOPMENTS IN CLINICAL PHARMACOLOGY. IN ADDITION, THE RECIPIENT WILL RECEIVE A $1,000 PRIZE AND A PLAQUE. TRAVEL EXPENSES, HOTEL EXPENSES AND MEETING REGISTRATION WILL BE REIMBURSED BY THE SOCIETY. SHEINER-BEAL PHARMACOMETRICS AWARD ELIGIBILITY: THE CANDIDATE MUST BE AN INVESTIGATOR OR LEADER WHO IS ACTIVELY ADVANCING THE SCIENTIFIC DISCIPLINE OF PHARMACOMETRICS AND/OR ITS IMPACT ON RESEARCH, DEVELOPMENT, REGULATORY EVALUATION, OR UTILIZATION OF THERAPEUTIC PRODUCTS, AND IS CAPABLE OF DELIVERING AN ENGAGING AND COMPREHENSIVE LECTURE ON PHARMACOMETRICS. THE AWARD IS INTENDED TO RECOGNIZE CLINICAL PHARMACOLOGISTS, CLINICIAN SCIENTISTS, COMPUTATIONAL SCIENTISTS, STATISTICIANS AND OTHERS IN ACADEMIA, INDUSTRY, GOVERNMENT AGENCIES, OR CONSULTING WHOSE WORK FALLS WITHIN THE SCOPE OF THE DEFINITION OF PHARMACOMETRICS. PRIZE AND PRESENTATION: THE SHEINER-BEAL PHARMACOMETRICS AWARD WILL BE PRESENTED ANNUALLY AT THE ASCPT ANNUAL MEETING. THE RECIPIENT WILL PRESENT A LECTURE SUMMARIZING THE WORKS THAT FORM THE BASIS OF THE AWARD. IN ADDITION, THE RECIPIENT WILL RECEIVE A $1,500 PRIZE AND A PLAQUE. TRAVEL EXPENSES, HOTEL EXPENSES AND MEETING REGISTRATION WILL BE REIMBURSED BY THE SOCIETY. WILLIAM B. ABRAMS AWARD IN GERIATRIC CLINICAL PHARMACOLOGY ELIGIBILITY: A NOMINEE MUST BE AN INVESTIGATOR IN GERIATRICS WHO IS ACTIVELY INVOLVED IN HIGH-QUALITY TEACHING AND RESEARCH IN GERIATRIC CLINICAL PHARMACOLOGY. PRIZE AND PRESENTATION: THE WILLIAM B. ABRAMS AWARD IN GERIATRIC CLINICAL PHARMACOLOGY IS PRESENTED AT THE ASCPT ANNUAL MEETING. THE RECIPIENT WILL RECEIVE A PLAQUE AND A $1,000 PRIZE. TRAVEL EXPENSES, HOTEL EXPENSES AND MEETING REGISTRATION WILL BE REIMBURSED BY THE SOCIETY. HENRY W. ELLIOTT DISTINGUISHED SERVICE AWARD ELIGIBILITY: A NOMINEE MUST BE A MEMBER OF ASCPT AND CANNOT HAVE HELD THE POSITION OF PRESIDENT-ELECT OR PRESIDENT OF THE SOCIETY WITHIN THE LAST FIVE YEARS. THE ESSENTIAL CRITERION IS DOCUMENTED EVIDENCE OF EXCELLENT SERVICE TO THE ORGANIZATION. ONE OR TWO OUTSTANDING ACTS OF SERVICE OR A LONG RECORD OF MANY ACTS OF SERVICE MAY JUSTIFY THE AWARD. THE RECIPIENT SHOULD HAVE A RECORD OF CONTINUOUS SERVICE TO THE SOCIETY, INCLUDING ONE OR MANY MAJOR ACCOMPLISHMENTS. PRIZE AND PRESENTATION: THE HENRY W. ELLIOTT DISTINGUISHED SERVICE AWARD IS PRESENTED AT THE ASCPT ANNUAL MEETING. THE RECIPIENT WILL RECEIVE A PLAQUE AND A $1,000 PRIZE. TRAVEL EXPENSES, HOTEL EXPENSES AND MEETING REGISTRATION WILL BE REIMBURSED BY THE SOCIETY. X X X X 0 0 0 0 0 0 0 1 0 Sharon J Swan FASAE CAE Chief Executive Officer 363316 0 0 0 21095 0 35000 0 11265 0 430676 0 0 0 Elise Laffman-Johnson Chief Operating Officer 163642 0 10000 0 396 0 12303 0 1100 0 187441 0 0 0 Part I, Line 7 The process for calculating the staff bonus is dependent on performance and discussions with the Compensation Committee and the CEO. The CEO's bonus is calculated based on achievement of incentive objectives that are approved by the Compensation Committee. Form 990, Part VI, Section A, line 6 The Society has two classes of members: FUll Member and Trainee/Student Member Full Member: For applicants who have earned a doctorate degree or equivalent in any of the biomedical sciences. Also for applicants in executive and leadership roles in related organizations. Applicants must demonstrate a sincere interest in, and contributions to, human pharmacology and therapeutics through publications, grants, patents, governmental reports, company reports, etc. Trainee/STudent Member: For applicants currently enrolled in a post-doctoral training program who have demonstrated an interest in human pharmacology and therapeutics. Also for applicants who are pursuing a post-baccalaureate degree and who possess an interest in human pharmacology and therapeutics. Form 990, Part VI, Section A, line 7a Members shall have such voting privileges as are determined from time to time by the Society's Governing Board and shall vote in such manner as determined by the Governing Board. Form 990, Part VI, Section A, line 7b Any changes to the organization's bylaws are subject to approval by the full members. Form 990, Part VI, Section B, line 11b The Form 990 is reviewed by the ASCPT Executive Director and ASCPT legal counsel following preparation by the Society's accountants. The officers of ASCPT review the document prior to it being filed. The Board is informed about the preparation and filing of the Form 990 and the return is made available at any time to any Board Member for his or her review. Form 990, Part VI, Section B, line 12c ALL ASCPT VOLUNTEER LEADERS COMPLETE A WRITTEN CONFLICT OF INTEREST DISCLOSURE. THE CEO, LEGAL COUNSEL, AND SENIOR STAFF ARE AWARE OF CONFLICTS, AND DISCUSS ANY ACTUAL OR POTENTIAL COI ISSUES. CONFLICT OF INTEREST IS DISCUSSED AT THE BEGINNING OF EVERY BOARD OF DIRECTORS CONFERENCE CALL, WITH BOARD MEMBERS BEING ASKED TO DECLARE ANY CONFLICTS AT THE BEGINNING OF THE CALL. Form 990, Part VI, Section B, line 15 THE EXECUTIVE DIRECTOR'S COMPENSATION IS DETERMINED BY THE ASCPT COMPENSATION COMMITTEE USING COMPARABILITY DATA. COMPENSATION OF KEY EMPLOYEES IS DETERMINED BY THE EXECUTIVE DIRECTOR USING COMPARABILITY DATA. Form 990, Part VI, Section C, line 19 The governing documents and conflict of interest policy are available on the ASCPT website. Financial statements are available upon request. Form 990, Part XII, Line 1: THE SOCIETY PREPARES ITS FINANCIAL STATEMENTS ON THE MODIFIED CASH BASIS OF ACCOUnTING. REVENUES ARE RECOGNIZED WHEN COLLECTED RATHER THAN WHEN EARNED, AND EXPENSES ARE GENERALLY RECOGNIZED WHEN PAID RATHER THAN WHEN INCURRED. THE MODIFIED CASH BASIS OF ACCOUNTING INCLUDES THE RECORDING OF DEPRECIATION ON PROPERTY AND EQuipMENT, AND REALIZED AND UNREALIZED GAINS AND LOSSES ON INVESTMENTS.